USA-based Mersana Therapeutics (Nasdaq: MRSN) has announced that the US Food and Drug Administration (FDA) has issued a partial clinical hold pausing patient enrollment in UP-NEXT and UPGRADE-A, the trials of UpRi in platinum-sensitive ovarian cancer.
Shares in the antibody-drug conjugate specialist closed 59% lower on Thursday following the announcement of the news.
UP-NEXT is a Phase III study while UPGRADE-A is a Phase I study.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze